Hereditary haemorrhagic telangiectasia (HHT) is a vascular hereditary autosomic dominant disease associated with epistaxis, telangiectases, gastrointestinal haemorrhages and arteriovenous malformations in lung, liverand brain. It affects 1-2 in 10, 000 people. There are at least three different genes mutated in HHT, ENG, ACVRL1 and MADH4 that encode endoglin, activin receptor-like kinase (ALK1) and Smad4 proteins, respectively. These proteins are involved in the transforming growth factor (TGF)-β superfamily signallingpathway of vascular endothelial cells. Mutations in ENG (HHT1) and ACVRL1 (HHT2) account for more than90% of all HHT mutations. In this article, we review the underlying molecular and cellular bases and thetherapeutic approaches that have been addressed in our laboratory in recent years.
CITATION STYLE
Bernabéu, C., Blanco, F. J., Langa, C., Garrido-Martin, E. M., & Botella, L. M. (2010). Involvement of the TGF-β superfamily signalling pathway in hereditary haemorrhagic telangiectasia. Journal of Applied Biomedicine. University of South Bohemia in Ceske Budejovice Faculty of Health and Social Sciences. https://doi.org/10.2478/v10136-009-0020-x
Mendeley helps you to discover research relevant for your work.